PATENT CLAIM ANALYSIS

Application Number: 16404059
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["424", "489000"]

Abstract:
The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Claim (Index 58):
A pharmaceutical composition, comprising:\n (a) particles consisting of\n (i) a protein kinase inhibitor having a degree of amorphicity of about 100% in an amount of from about 10% by weight to about 40% by weight of the particles; and \n (ii) at least one polymeric stabilizing and matrix-forming component in an amount of about 60% by weight to about 90% by weight of the particles; \n wherein the protein kinase inhibitor is dasatinib, dasatinib hydrate, dasatinib solvate, dasatinib salt, or combinations thereof.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 100.0
- Lexical Diversity: 1.48718
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16404004', '16403969', '16404027', '15248107', '15791093']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8966263066616389
- 35 USC 102 Novelty (BERT): 0.696495332655183
- Combined Prediction Score: 0.8766132092609933
- Mean Citation Score: 853.8148140000003
- Max Citation Score: 856.69073
- Similarity Product: 713.0518364433314

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test